In some cases, after the first use of the drug may develop hypersensitivity and allergic reactions, which should immediately inform the doctor. Very rarely even after the first use of the drug, anaphylactic reactions can progress to a life-threatening anaphylactic shock. In these cases, the treatment with moxifloxacin should be stopped and the necessary medical measures (including anti-shocks) should be initiated. With the use of moxifloxacin in some patients, lengthening of the interval QT. Because women have a longer interval than men QT, they may be more sensitive to drugs that extend the interval QT. Elderly patients are also more prone to the effects of drugs that affect the interval QT.
Interval lengthening QT is associated with an increased risk of ventricular arrhythmias, including polymorphic ventricular tachycardia.
Degree of lengthening interval QT may increase with increasing drug concentration, therefore, do not exceed the recommended dose and infusion rate (400 mg for 60 min). However, in patients with pneumonia, the correlation between the concentration of moxifloxacin in the blood plasma and the lengthening of the interval QT it was noted. None of the 9,000 patients who received moxifloxacin, there were no cardiovascular complications and lethal cases associated with lengthening the interval QT. With the use of moxifloxacin, the risk of developing ventricular arrhythmias in patients with predisposing arrhythmias may increase.
In this regard, the drug is contraindicated:
- with changes in the electrophysiological parameters of the heart, expressed in the lengthening of the interval QT: Congenital or acquired documented lengthening interval QT, electrolyte disturbances. especially unadjusted hypokalemia; clinically significant bradycardia; clinically significant heart failure with a reduced fraction of the left ventricular ejection; in the presence of a history of rhythm disorders, accompanied by clinical symptoms;
- when used with other drugs that extend the interval QT (see the section "Interaction with other medicinal products").
Moxifloxacin should be used with caution:
- in patients with potentially proarrhythmic conditions, such as acute myocardial ischemia and cardiac arrest;
- in patients with cirrhosis of the liver (since this category of patients can not exclude the risk of developing an extension of the interval QT).
When moxifloxacin was used, cases of fulminant hepatitis, potentially leading to hepatic insufficiency (including fatal cases) were reported (see "Side effect"). The patient should be informed that if symptoms of hepatic insufficiency occur, the doctor should be consulted before continuing with moxifloxacin therapy.
When moxifloxacin was taken, cases of development of bullous skin lesions (Stevens-Johnson syndrome, toxic epidermal necrolysis) were reported. The patient should be informed that in case of symptoms of skin or mucous membrane damage, the doctor should be consulted before continuing with moxifloxacin therapy.
The use of drugs quinolone series is associated with a possible risk of development of convulsive seizure. Moxifloxacin should be used with caution in patients with CNS diseases and with CNS disorders, predisposing to the occurrence of seizures or reducing the threshold of convulsive activity.
The use of broad-spectrum antibacterial drugs, including moxifloxacin, is associated with a risk of developing pseudomembranous colitis. This diagnosis should be kept in mind in patients who have severe diarrhea with moxifloxacin. In this case, immediately be appointed appropriate therapy. Drugs that inhibit the peristalsis of the intestine are contraindicated in the development of severe diarrhea.
Moxifloxacin should be used with caution in patients with myasthenia gravis gravis in connection with a possible exacerbation of the disease.
Against the background of quinolone therapy, including moxifloxacin, tendonitis and tendon rupture are possible, especially in elderly patients and patients receiving glucocorticosteroids. Cases that occurred a few months after the completion of treatment are described.At the first symptoms of pain or inflammation at the site of damage, the drug should be stopped and unloaded.
When applying quinolones, photosensitivity reactions are noted. However, in pre-clinical and clinical studies, as well as with the use of moxifloxacin, no photosensitivity reactions were observed in practice. Nevertheless, patients receiving moxifloxacin, should avoid exposure to direct sunlight and ultraviolet light.
It is not recommended to use moxifloxacin for the treatment of infections caused by strains Staphylococcus aureus, resistant to methicillin (MRSA). In the case of suspected or confirmed infections caused by MRSA, should be prescribed treatment with appropriate antibacterial drugs (see the section "Pharmacodynamics").
The ability of moxifloxacin to inhibit the growth of mycobacteria can cause interaction in vitro moxifloxacin with a Mycobacterium spp., leading to false-negative results in the analysis of samples of patients treated with moxifloxacin during this period.
In patients treated with quinolones, including moxifloxacin, described cases of sensory or sensorimotor polyneuropathy, leading to paresthesia, hyposthenia, dysesthesia, or weakness. Patients undergoing treatment with moxifloxacin should be warned of the need to seek immediate medical attention before continuing treatment in the event of symptoms of neuropathy, including pain, burning, tingling, numbness, or weakness (see "Side effect" section).
Reactions from the psyche may occur even after the first use of fluoroquinolones, including moxifloxacin. In very rare cases, depression or psychotic reactions progress to the occurrence of suicidal thoughts and behavior with a tendency to self-harm, including suicidal attempts (see section "Side effect"),
In case of development in patients such reactions should be canceled moxifloxacin and take the necessary measures. Caution should be exercised when using moxifloxacin in patients with psychoses and / or psychiatric illnesses in the anamnesis.
Disglycemia
As in the case of other fluoroquinolones, the use of moxifloxacin showed a change in the concentration of glucose in the blood, including hypo- and hyperglycemia. Against the background of moxifloxacin therapy, disglycemia occurred mainly in elderly patients with diabetes mellitus receiving concomitant therapy with oral hypoglycemic drugs (eg, sulfonylureas) or insulin. When performing treatment in patients with diabetes mellitus, careful monitoring of the concentration of glucose in the blood is recommended (see section "Side effect").
Patients who follow a diet with a low salt content (with heart failure, kidney failure, with nephrotic syndrome) should take into account that the infusion solution contains sodium chloride. The daily dose of sodium in the preparation is 34 mmol.